A Randomized, Controlled, 6-treatment, 6-sequence, 6-period Cross-over Dose Response Study of 3 Single Doses of Afrezza Inhaled Technosphere Insulin and of 3 Single Doses of SC Insulin Lispro in Patients With Diabetes Mellitus Type 1 Using the Euglycemic Clamp Technique

Trial Profile

A Randomized, Controlled, 6-treatment, 6-sequence, 6-period Cross-over Dose Response Study of 3 Single Doses of Afrezza Inhaled Technosphere Insulin and of 3 Single Doses of SC Insulin Lispro in Patients With Diabetes Mellitus Type 1 Using the Euglycemic Clamp Technique

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Insulin (Primary) ; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors MannKind Corporation; Sanofi
  • Most Recent Events

    • 02 Oct 2017 According to a Mannkind Corporation media release, the U.S. Food & Drug Administration (FDA) has approved an update to the Afrezza prescribing information to include data from this trial.
    • 12 Jun 2016 Results were presented at the American Diabetes Association's 76th Scientific Sessions (ADA) 2016, according to a Mannkind Corporation media release.
    • 12 Jun 2016 Results published in a Mannkind Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top